Twinbeech Capital LP Prothena Corp Public LTD CO Transaction History

Twinbeech Capital LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$32.31 - $52.32 $1.28 Million - $2.08 Million	39,720 Added 216.15%	58,096 $2.11 Million
Q3 2023 Nov 14, 2023	BUY	$47.3 - $70.6 $869,184 - $1.3 Million	18,376 New	18,376 $886,000
Q2 2022 Aug 15, 2022	SELL	$22.73 - $39.98 $417,641 - $734,592	-18,374 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$30.27 - $49.22 $556,180 - $904,368	18,374 New	18,374 $672,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.